Provided are a fusion antigen of porcine Getah virus (GETV), a kit, a preparation method therefor and an application thereof. The fusion antigen of the GETV is primarily prepared by recombining a Gaussia luciferase (GLuc) gene with a codon- optimized GETV E2 antigen gene to construct an expression vector, and transfecting the expression vector containing GLuc-E2 into mammalian cell lines, resulting in the secretion of GLuc-E2 proteins into a cell supernatant for expression. Without the need for protein purification step, the cell supernatant may be directly collected for disease detection. The present disclosure demonstrates strong specificity and shows no cross- reactivity with African swine fever virus (ASFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 (PCV2), pseudorabies virus (PRV), or Japanese encephalitis virus (JEV).

Provided herein are enhanced luciferase enzymes for use with thermostable luciferin analogs for bioluminescent assays. In particular, the present disclosure provides compositions, assays, and methods for performing a bioluminescent assay using enhanced, high-activity luciferase enzymes compatible with thermostable luciferins, such as 5,5-disubstituted luciferin analogs.

There are SARS coronavirus 2 recombinant vectors derived from a GH clade SARS coronavirus 2 Korean isolate, which express distinct reporter genes, and the production method thereof. A full-length clone of a SARS coronavirus 2 Korean isolate or a derivative thereof, according to one embodiment, can be used as a standard material for evaluating the efficacy of therapeutic agents and vaccines in cell lines and animal models while maintaining infectivity and replication capacity when restored to viruses, can be used to develop a large-scale testing method for therapeutic agent development, and can be used to develop attenuated vaccine strains. In addition, a SARS coronavirus 2 recombinant vector derived from a Korean isolate or a derivative thereof, expressing a reporter gene, can be used for high-capacity, rapid drug screening in the development of antibody therapeutic agents and antiviral agents.

Disclosed herein are devices, methods, and systems for rapid detection of microorganisms using a recombinant bacteriophage. The specificity of recombinant bacteriophages for binding microorganisms allows targeted and highly specific detection of a microorganism of interest.